Cantor Fitzgerald Brokers Reduce Earnings Estimates for SLDB

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Solid Biosciences in a research note issued to investors on Thursday, May 22nd. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($2.06) per share for the year, down from their prior estimate of ($1.60). Cantor Fitzgerald has a "Overweight" rating and a $16.00 price target on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

SLDB has been the topic of several other reports. Wedbush reduced their price objective on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Barclays lowered their price objective on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a research report on Friday, May 16th. Piper Sandler decreased their target price on Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Friday, May 16th. Chardan Capital reduced their price objective on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Finally, JPMorgan Chase & Co. cut their price target on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating for the company in a research note on Thursday, March 13th. Ten analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $14.90.

Solid Biosciences Price Performance

SLDB traded down $0.08 during trading hours on Monday, reaching $3.19. The company's stock had a trading volume of 351,287 shares, compared to its average volume of 1,077,497. The stock has a market cap of $246.89 million, a PE ratio of -1.05 and a beta of 2.32. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37. The business's 50-day moving average is $3.18 and its 200-day moving average is $4.06.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06).

Institutional Trading of Solid Biosciences

Several large investors have recently bought and sold shares of the company. Bain Capital Life Sciences Investors LLC boosted its stake in shares of Solid Biosciences by 96.1% during the first quarter. Bain Capital Life Sciences Investors LLC now owns 7,911,669 shares of the company's stock valued at $29,273,000 after acquiring an additional 3,877,087 shares during the last quarter. Siren L.L.C. lifted its position in Solid Biosciences by 97.8% during the first quarter. Siren L.L.C. now owns 7,415,905 shares of the company's stock worth $27,439,000 after buying an additional 3,666,864 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Solid Biosciences by 285.0% during the first quarter. Adage Capital Partners GP L.L.C. now owns 6,729,484 shares of the company's stock worth $24,899,000 after buying an additional 4,981,400 shares during the period. Vestal Point Capital LP raised its holdings in shares of Solid Biosciences by 1.8% in the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock worth $11,400,000 after purchasing an additional 50,000 shares during the period. Finally, Redmile Group LLC raised its holdings in shares of Solid Biosciences by 228.2% in the 1st quarter. Redmile Group LLC now owns 2,019,171 shares of the company's stock worth $7,471,000 after purchasing an additional 1,403,925 shares during the period. Institutional investors and hedge funds own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.